Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsAurobindopharma

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Prefer Aurobindo Pharma, Mindtree, SKS Micro: Dipan Mehta

      Dipan Mehta, Member at BSE & NSE is of the view that one may prefer Aurobindo Pharma, Cadila Healthcare and Torrent Pharmaceuticals from pharmaceutical space.

    • Samvat 2072: Top Diwali portfolio picks by Dipan Mehta

      Dipan Mehta, Member at BSE & NSE is of the view that one can add selective banks, auto, pharma and FMCG stocks in the portfolio.

    • Aurobindo Pharma may test Rs 980, says Daljeet Singh Kohli

      Daljeet Singh Kohli of India Nivesh Securites is of the view that Aurobindo Pharma may test Rs 980.

    • Bull's Eye: Sell Dr Reddy's, JSW Energy, Ceat, buy BoI

      Manas Jaiswal of manasjaiswal.com advises buying Bank of India with a target of Rs 142.

    • Sell Ceat, HDIL, IRB Infra, Aurobindo Pharma: Rakesh Bansal

      Rakesh Bansal of RK Global recommends selling Ceat, HDIL, IRB Infra and Aurobindo Pharma.

    • Bull's Eye: Buy Eros, VIP Ind, Sun TV, UBL, sell HDIL, Ceat

      Vishal Malkan of malkansview.com is of the view that one may buy Ashok Leyland with a target of Rs 97.

    • Prefer Glenmark Pharma, Aurobindo Pharma: Vishal Malkan

      Vishal Malkan of malkansview.com is of the view that one may prefer Glenmark Pharma and Aurobindo Pharma.

    • Buy Lupin near to Rs 1650, Sun Pharma looks good: RK Global

      Rakesh Bansal of RK Global is of the view that one can buy Lupin at around Rs 1650 and feels that Granules India, Sun Pharmaceutical Industries and Aurobindo Pharma look good at current level.

    • Prefer Cadila Healthcare: Neeraj Deewan

      Neeraj Deewan of Quantum Securities is of the view that one may prefer Cadila Healthcare.

    • Go long in Aurobindo Pharma, target Rs 830: CA Rudramurthy

      CA Rudramurthy of Vachana Investments is of the view that one may go long in Aurobindo Pharma with a target of Rs 830.

    • Top buzzing midcap stocks to trade on October 21

      Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have Indiabulls Real Estate, Mphasis, Federal Bank, Torrent Pharma, Dr Reddys Laboratories & Aurobindo Pharma.

    • Aurobindo Pharma, Sun Pharma preferred picks: Joshi

      Mayuresh Joshi of Angel Broking is of the view that Aurobindo Pharma and Sun Pharma are the preferred picks.

    • 6 stocks likely to see lot of action today

      Aditya Agarwal of Way2Wealth Securities is of the view that one may sell Wipro with a target of Rs 565.

    • Buy Aurobindo Pharma, target Rs 960: Daljeet Singh Kohli

      Daljeet Singh Kohli of India Nivesh Securities recommends buying Aurobindo Pharma with a target of Rs 960.

    • Look at Infosys, Aurobindo Pharma: CK Narayan

      CK Narayan, MD of Growth Avenues is of the view that one may look at Infosys and Aurobindo Pharma.

    • Optimistic on Sun Pharma, target Rs 950: Mayuresh Joshi

      Mayuresh Joshi, Fund Manager (PMS) at Angel Broking is extremely optimistic on Sun Pharma with a target of Rs 950.

    • Look at Aurobindo Pharma: Mayuresh Joshi

      Mayuresh Joshi, Fund Manager (PMS) at Angel Broking is of the view that one may look at Aurobindo Pharma.

    • Buy Shriram Transport, OBC; sell Aurobindo Pharma: LKP Sec

      Gaurav Bissa of LKP Securities recommends buying Shriram Transport Finance Corporation and OBC and advises selling Aurobindo Pharma.

    • Sell Aurobindo Pharma, says Kunal Bothra

      Kunal Bothra of LKP Securities recommends selling Aurobindo Pharma.

    • Bull's Eye: Buy JK Tyre, NIIT, Adani Power, Punj Lloyd

      Manish Sharma of Destimoney Securities is of the view that one may sell Federal Bank with a target of Rs 61.

    • Look at Dr Reddy's Labs, Aurobindo Pharma: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can look at Dr Reddy's Laboratories, Aurobindo Pharma and Cadila Healthcare from the pharma space.

    • Pick Glenmark Pharma, Aurobindo Pharma: Vishal Malkan

      Vishal Malkan of malkansview.com is of the view that one may pick Glenmark Pharma and Aurobindo Pharma from the pharma space.

    • Hold Ballarpur Industries, says Kunal Bothra

      According to Kunal Bothra of LKP Securities, one may hold Ballarpur Industries.

    • Buy Aurobindo Pharma 760 Call, pick Infosys: VK Sharma

      VK Sharma of HDFC Securities suggests buying Aurobindo Pharma 760 Call and Infosys 1160 Call.

    • Pick Mindtree, Strides Arcolab, Aurobindo: CK Narayan

      CK Narayan, MD, Growth Avenues Asset Advisors is of the view that one may pick Mindtree, Strides Arcolab and Aurobindo Pharma.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347